Evaluating Investment Choices: Johnson & Johnson vs. Healthcare ETFs

Investors often face a critical decision when exploring opportunities in the healthcare sector: should they invest in individual companies like Johnson & Johnson or choose a healthcare ETF that offers broader market exposure? While ETFs may appear to provide a safer option due to their inherent diversification, this perception can be misleading. This article presents a comprehensive comparison between Johnson & Johnson and the iShares U.S. Healthcare ETF (IYH), empowering investors to make informed decisions about their portfolios.

Understanding Your Investment Choices

Johnson & Johnson Overview

Johnson & Johnson stands as a prominent single company with a diversified portfolio spanning pharmaceuticals and medical technology.

iShares U.S. Healthcare ETF (IYH) Overview

The IYH ETF comprises approximately 100 healthcare stocks but is predominantly weighted towards large-cap companies.

Analyzing Return Profiles

Return Profile of Johnson & Johnson

The performance of Johnson & Johnson is influenced by several factors:

• Pharmaceutical pipeline execution
• Margin stability
• Capital allocation

Growth expectations for Johnson & Johnson remain modest, with revenue guidance projected in the mid-single digits, resulting in steady compounding supported by income.

Return Profile of iShares U.S. Healthcare ETF (IYH)

The ETF provides exposure to major players like Eli Lilly and AbbVie. Long-term returns have averaged around 10.7% annually over the past decade, but these results are largely driven by a small number of significant holdings. The dividend yield is low, indicating that most returns depend on price appreciation.

Identifying Risks in Investments

Concentration Risk

While Johnson & Johnson carries the risk associated with a single company, it is internally diversified. In contrast, IYH appears diversified but is significantly influenced by a few large holdings, creating hidden concentration risks.

Sector Risk

Johnson & Johnson benefits from its mixed business model, providing some insulation from sector-specific pressures. Conversely, IYH is fully exposed to risks such as:

• Pricing pressure
• Regulatory changes
• Declining margins

Valuation Risk

Johnson & Johnson is generally viewed as being closer to fair value, offering a margin of safety. In contrast, IYH trades at elevated levels compared to its underlying fundamentals, making it more susceptible to declines in valuation.

Volatility Assessment

Historically, Johnson & Johnson has acted as a defensive asset, while IYH has experienced significant drawdowns, including a nearly 28% decline in 2020.

Structural Risk

Johnson & Johnson faces company-specific risks, including litigation and pipeline execution challenges. IYH, on the other hand, is subject to broader structural risks affecting the entire healthcare sector, which are more difficult to mitigate.

Evaluating Risk-Adjusted Returns

In terms of risk-adjusted returns:

• Johnson & Johnson offers lower volatility, stable earnings, and income support.
• IYH presents higher volatility, concentration within the sector, and limited income support.

Despite its apparent diversification, the ETF does not necessarily provide better risk-adjusted returns than Johnson & Johnson.

Decision-Making Framework

Consider choosing Johnson & Johnson if you seek:

• Stability
• Income
• Predictable compounding

Alternatively, opt for IYH if you desire:

• Sector exposure
• Participation in multiple winners
• A more tactical allocation

In summary, many investors assume that ETFs are the safer option. However, in this case, that assumption may not hold. The ETF introduces hidden concentration risks, full sector exposure, and heightened sensitivity to structural pressures, whereas Johnson & Johnson provides a more controlled risk environment and a stable return path.

Chapwood Investments, LLC, is a partner of Ethos Financial Group, LLC, a Securities and Exchange Commission-registered investment advisor. No mention, opinion, or omission of a particular security, index, derivative, or other instrument in this article constitutes an opinion on the suitability of any security. The information and data presented here were obtained from sources deemed reliable, but their accuracy and completeness are not guaranteed. At any given time, principals at Chapwood Investments, LLC may or may not have a financial interest in any or all of the securities or instruments discussed in this article. Guest contributors do not receive compensation and do not provide endorsements or testimonials. Past performance is not indicative of future results.

Exchange Traded Funds (ETFs) are sold by prospectus. Please consider the investment objectives, risks, charges, and expenses carefully before investing. The prospectus, which contains this and other information about the investment company, can be obtained from the Fund Company or your financial professional. Be sure to read the prospectus carefully before deciding whether to invest.